摘要
目的探究雷贝拉唑四联疗法对幽门螺杆菌(Hp)阳性慢性胃炎患者环氧化酶-2(COX-2)、钙粘附蛋白E(E-cadherin)的影响。方法选取我院2018年9月至2019年9月收治的120例Hp阳性慢性胃炎患者,以数字随机表法将其分为观察组(n=60,雷贝拉唑四联疗法)和对照组(n=60,常规四联疗法)。比较两组的治疗效果。结果治疗后,观察组的COX-2、E-cadherin、血清MIF、MMP-9水平均明显低于对照组(P<0.05)。观察组Hp根除率为96.67%,明显高于对照组的83.33%(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论雷贝拉唑四联疗法在Hp阳性慢性胃炎患者中的应用价值较高,可提高Hp根除率,下调COX-2、E-cadherin、MIF、MMP-9水平,且不增加不良反应。
Objective To explore the effect of rabeprazole quadruple therapy on cyclooxygenase-2(COX-2)and E-cadherin(E-cadherin)in patients with Helicobacter pylori(Hp)positive and chronic gastritis.Methods A total of 120 patients with Hp positive and chronic gastritis admitted in our hospital from September 2018 to September 2019 were divided into observation group(n=60,rabeprazole quadruple therapy)and control group(n=60,conventional quadruple therapy)by digital random table method.The therapeutic effects of the two groups were compared.Results After treatment,COX-2,E-cadherin,serum MIF and MMP-9 levels in the observation group were significantly lower than those in the control group(P<0.05).The Hp eradication rate in the observation group was 96.67%,which was significantly higher than 83.33%in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Rabeprazole quadruple therapy for patients with Hp positive and chronic gastritis has higher application value,it can improve the Hp eradication rate,down-regulate the levels of COX-2,E-cadherin,MIF,MMP-9,and no increase in adverse reactions.
作者
周晓
史志红
ZHOU Xiao;SHI Zhihong(Gastroenterology Department,Xinxiang First People's Hospital,Xinxiang 453000,China)
出处
《临床医学研究与实践》
2021年第4期60-61,64,共3页
Clinical Research and Practice
关键词
雷贝拉唑
四联疗法
幽门螺杆菌
慢性胃炎
rabeprazole
quadruple therapy
Helicobacter pylori
chronic gastritis
作者简介
周晓(1985-),男,汉族,河南新乡人,主治医师,学士。研究方向:消化内科相关疾病。
